Relmada Therapeutics, Inc. (RLMD) Stock: Price, Forecast & Analyst Target
Relmada Therapeutics, Inc. (RLMD) — MoonshotScore 58/100 (Fair band), calculated Nov 18, 2026. Price $3.11 (+8.93%), as of the Nov 19, 2026 trading session; market cap $332M.
Educational signal · not a buy or sell recommendation · How to read this
Relmada Therapeutics, Inc. · RLMD · NASDAQ
Relmada Therapeutics, Inc. is a clinical-stage biotechnology company focused on developing treatments for central nervous system (CNS) diseases.
Price as of Nov 19, 2026
Key Statistics
MoonshotScore v2 · Relmada Therapeutics (RLMD)
FairWhy this rating? Method, drivers & history
Bands for the MoonshotScore: Exceptional 80-100 · Strong 65-79 · Fair 45-64 · Weak below 45.
- Business Quality — Is this a genuinely good business?
- Financial Safety — Could this blow up on me?
- Valuation — Am I paying a fair price?
- Growth Durability — Is the growth real and likely to last?
- Momentum — Is the market already moving on this?
A fortress balance sheet, but weak growth and a full valuation. Business Quality: Average; Financial Safety: Fortress; Valuation: Full; Growth Durability: Fading; Momentum: Slipping.
- EPS beat 3 of the last 8 reports
- Altman Z 18.07 · Piotroski F 2
- ROE -64.7% · ROA -36.9% · current ratio 26.37
Holding back: weak price trend
Helping: balance-sheet strength
What has the MoonshotScore done over time?
| Recorded | Score | Band |
|---|---|---|
| 62 | Fair | |
| 63 | Fair | |
| 62 | Fair | |
| 62 | Fair | |
| 58 | Fair | |
| 58 | Fair |
Daily score refresh is delayed. This is the last recorded calculation.
Calculation uses the most recent completed US trading session. Live price changes do not update the score immediately.
Computed · How the MoonshotScore is computed →
Price & valuation
| Measure | Value | As of |
|---|---|---|
| Latest provided price | $3.11 | |
| Change on the day | +8.93% | |
| 52-week range | $3.07 – $8.00 | |
| Market capitalisation | $332M | — |
| Shares traded on the day | 1.71M |
Price & events
Other perspectives
Council score for Relmada Therapeutics (RLMD): perspectives
Council is a separate blend of available disciplines; MoonshotScore above remains the five-pillar research rating.
5-Factor Breakdown
Legends Council
4 lenses, 0 current
AI simulations built from the named investors' published principles. Not affiliated with, endorsed by, or the opinion of these individuals. How these lenses are built
Read on: Sep 10, 2026 · older than the 27 hours refresh window; not a current reading
Munger's Mindset
Balance Sheet & Valuation · historical
Read on: Sep 10, 2026 · older than the 27 hours refresh window; not a current reading
How to read these bars and different assessments
Council is a separate blend of available disciplines; MoonshotScore above remains the five-pillar research rating.
Bars show each model's ordered assessment on its own scale, not a probability or a comparable investment return. The adjacent words give the assessment; more filled segments indicate a stronger model reading.
On Sep 10, 2026, the Munger lens read the price at that time as undervalued against its own estimate of value.
Readings on this page are from Nov 20, 2026, except a card that shows its own read date.
What is Relmada Therapeutics (RLMD), and what does it report?
Short answer
A current FMP business description is unavailable; the listing and provider classification below are the available identity facts. Relmada Therapeutics, Inc. (RLMD) is listed on NASDAQ. It employs 17 people and is led by Sergio Traversa. The market values it at $332M.
What do the latest results show for Relmada Therapeutics (RLMD)?
Short answer · as of
Against analyst estimates the company has EPS beat 3 of the last 8 reports.
What are the financial strengths and risks for Relmada Therapeutics (RLMD)?
Short answer
The MoonshotScore pillars rate balance-sheet strength as strengths. What is holding it back is weak price trend. The distress and quality screens read Altman Z 18.07 · Piotroski F 2. Trailing ratios: ROE -64.7% · ROA -36.9% · current ratio 26.37.
Data-derived red flags
- Negative return on equity (-64.7%) — the business is not currently generating profit on shareholder capital.
- Inconsistent delivery — missed Wall Street EPS estimates in 5 of the last 8 reported quarters.
- Weak fundamentals — a Piotroski F-Score of 2/9 flags soft profitability, leverage or efficiency.
What should you watch next at Relmada Therapeutics (RLMD)?
Short answer · as of
Analyst estimates on file carry FY2026 revenue $10.00M · EPS -0.56 · 3 analysts. Current published price targets run low $12.00 · high $12.00 · consensus $12.00 · median $12.00 against a quoted price of $3.11 (as of Nov 19, 2026).
What the records here don't tell us
- The next earnings date is not yet scheduled in the calendar we read.
- No quarterly income statement is held for RLMD.
Checked against the records this page reads, on the dates shown above.
How does Relmada Therapeutics compare with its peers?
Short answer
Relmada Therapeutics's score ranks 13th of 13 in the bounded comparison shown, against 12 same-model peers. These are company scores, not expected investment returns. The set lists named competitors first, then companies in the same data-provider industry classification closest in market value; that classification is the provider's, not our judgment of business similarity.
| Company | Price | Market value | Score |
|---|---|---|---|
| $1382.75 Nov 18, 2026 | $1.23T | 98 5-pillar Nov 18, 2026 | |
| $13.33 Nov 18, 2026 | $471M | 91 5-pillar Nov 18, 2026 | |
| $9.07 Nov 19, 2026 | $540M | 91 5-pillar Nov 18, 2026 | |
| $3.06 Nov 19, 2026 | $258M | 90 5-pillar Nov 18, 2026 | |
| $42.53 Nov 18, 2026 | $801M | 88 5-pillar Nov 18, 2026 | |
| $272.70 Nov 18, 2026 | $656B | 83 5-pillar Nov 18, 2026 | |
| $286.01 Nov 18, 2026 | $506B | 83 5-pillar Nov 18, 2026 | |
| $3.89 Nov 18, 2026 | $169M | 72 5-pillar Nov 18, 2026 | |
| $1.88 Nov 19, 2026 | $178M | 69 5-pillar Nov 18, 2026 | |
| $12.17 Nov 19, 2026 | $861M | 69 5-pillar Nov 18, 2026 | |
| $9.28 Nov 19, 2026 | $545M | 68 5-pillar Nov 18, 2026 | |
| $30.78 Nov 19, 2026 | $1.03B | 64 5-pillar Nov 18, 2026 | |
| Relmada Therapeutics (RLMD) — this page | $3.11 | $332M | 58 |
Only 5-pillar scores are ranked together. Other models are not directly comparable. Price and score dates are shown separately; market-value dates are unavailable.
The records behind this page
Analyst targets & estimates
What analysts have on file
- Price target, low to high
- $12.00 – $12.00
- Consensus target
- $12.00
- Median target
- $12.00
- Revenue estimate
- $10.00M
- EPS estimate
- $-0.56
Consensus record · Captured .
Measured against a quoted price of $3.11 (as of Nov 19, 2026).
Insider activity
Form 4 records via FMP · Of the newest 100 records, those within the last 180 days, newest dated Sep 10, 2026
- Transactions
- 4
- Identified insiders
- 2
- Purchases
- 4
- Sales
- 0
- Other transactions
- 0
Purchases and sales use the reported transaction category. Other transactions include awards, exercises, gifts, withholding and unclassified activity; an acquisition or disposition alone is not a purchase or sale. These records do not establish intent.
Who holds the shares?
Institutional ownership reported through 13F filings.
Tracked investors
Which of the 16 named investors we follow held RLMD in their latest 13F filing, and what they did against the filing before it.
None of the 16 tracked investors reported RLMD in their latest 13F filing.
How to read these figures
These filings arrive after the quarter ends. Names appear as the provider lists them, not as a verified ranking, and without filing dates. Related managers can appear separately, so their shares are not added together. Tracked investors: each fund's own latest 13F, so funds that have not filed the newest quarter yet show their previous one; weight is the share of the fund's reported 13F value.
What has been published about Relmada Therapeutics (RLMD)?
- Relmada Therapeutics Appoints Jørn Skibsted Jakobsen as Chief Development Officer, Urology & Uro-Oncology
- Relmada Therapeutics Appoints Uro-Oncology Leader Jørn Skibsted Jakobsen, MD, PhD, as Chief Development Officer
- Relmada Therapeutics, Inc. Q3 2026 Earnings Call Summary
- Relmada (RLMD) Q3 2026 Earnings Call Transcript
What Investors Ask About Relmada Therapeutics (RLMD)
These answers are editorial: they are written from question templates that restate figures shown above. They are not part of the source register.
What does the MoonshotScore mean for RLMD?
RLMD carries the MoonshotScore stated above — the Fair band. This is an educational research signal, not a buy or sell recommendation. The number comes from the five-pillar engine (business quality, financial safety, valuation, growth durability, momentum), re-ranked daily against sector peers.
Is RLMD a good stock to buy?
Stock Expert AI does not rate RLMD buy, sell or hold. Relmada Therapeutics, Inc. carries a MoonshotScore, in the Fair band, a research rating against its peers rather than a forecast. Whether it fits is your call: check what it sells, whether it earns and what the price assumes. This is educational content, not investment advice.
What is the RLMD stock price today?
The last price recorded for Relmada Therapeutics, Inc. (RLMD), with its trading session and source, is listed under Price & valuation on this page. It is a provider snapshot, not a live exchange feed, so check a brokerage quote before you trade.
What is the RLMD price target?
The analyst consensus price target for Relmada Therapeutics, Inc. (RLMD), with its range and the date it was captured from FMP, is listed under Analyst targets & estimates on this page. Targets are analyst opinions and change often; they are not a Stock Expert AI forecast.
What are the key factors to evaluate for RLMD?
Relmada Therapeutics, Inc. (RLMD) holds a MoonshotScore in the moderate range. To weigh it, read the analyst view under Analyst targets & estimates on this page. Success in these indications would diversify Relmada's product pipeline and reduce its reliance on MDD. Not financial advice.
How frequently does RLMD data refresh on this page?
RLMD's price is the last quote we recorded, from the Nov 19, 2026 trading session. Pages are served from a cache, so the copy you are reading can lag that quote. The quote is a provider snapshot, not an exchange feed. Fundamentals follow quarterly filings. V2 is recalculated from the most recent completed US trading session; the score's own date shows its last successful run.
What has driven RLMD's recent stock price performance?
Relmada Therapeutics, Inc. (RLMD) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Novel drug candidate (Esmethadone) with a unique mechanism of action. See the News tab for the latest drivers. Past performance does not predict future results.
Should investors consider RLMD overvalued or undervalued right now?
Relmada Therapeutics, Inc. (RLMD) has no trailing P/E available here, so lean on price-to-sales and cash flow in the Financials tab. Its analyst consensus target is listed under Analyst targets & estimates on this page. Compare P/E, P/S, and EV/EBITDA against sector peers for a full view.
Can I buy fractional shares of RLMD?
Fractional-share availability for Relmada Therapeutics, Inc. (RLMD) depends on your brokerage, account and supported securities. Check the broker's current eligibility, minimums and fees before placing an order.
Machine-generated analysis by Stock Expert AI — model gemini-2.0-flash, generated May 10, 2026. Editorial oversight is systemic, not page-by-page. Editorially accountable: Sedat ANAK, Founder and Editor-in-Chief.
Sources: the source register lists the 20 figures on this page — 9 from Financial Modeling Prep (FMP), 10 with no recorded source and 1 from Stock Expert AI's own score and rank. Its rows (value as shown, as-of date, tier and source link) are in the Markdown version of this page.
Publication details and research sources
- Published
- Research standards
- Methodology · Editorial policy · Corrections
- Report a number
- sedat@stockexpertai.com